REDONDO BEACH, CA--(Marketwired - Oct 28, 2016) - SECFilings.com, a leading financial news and information portal offering free real time public company filing alerts, announces the publication of an article discussing the role Endonovo Therapeutics Inc. (OTCQB: ENDV) plays in the emerging multi-billion dollar electroceutical industry.
Starting with the advent of the pacemaker and cochlear implants, physicians have for decades been using small jolts of electricity within the human body to stimulate activity. Though this method of treatment is clearly successful, the technology necessary to take "electroceuticals" to the next level simply wasn't there until the recent advancements in technology.
Some of the more well-known electroceutical devices approved by the FDA in recent years include a device that is implanted in the body in order to stimulate airway muscles to treat sleep apnea, and another that is an implanted weight control device that stimulates the vagus nerve in order to make a person feel full. Kristoffer Famm, head of the bioelectronics unit at GlaxoSmithKline, predicts an endless array of devices to come. "The nervous system is crisscrossing our viscera to control many aspects of our organ function," he states. "Rather than targeting cells with a drug, treatments could send an electrical pulse to a major nerve to alter the commands an organ receives, and thereby control its function." No small player in the healthcare industry, GSK recently joined forces with Verily Life Sciences to form Galvani Bioelectronics "to enable the research, development, and commercialization of bioelectronics medicines."
The idea is that miniature devices can be used to trigger biochemical processes that are typically manipulated by pharmaceutical drugs, which often times have far reaching side-effects well beyond treating the issue at hand. The ability to miniaturize these devices allows the reduction of procedure times, patient complications, and post-surgical pain.
But, what if, instead of implanting devices into the body, the same effect could be achieved through 100% non-invasive treatments?
This is where Endonovo Therapeutics (OTCQB: ENDV), a company focused on developing a bioelectronic approach to regenerative medicine, differs from the above-mentioned examples, as their Immunotronics™ platform is non-invasive.
Click here to read the full article: http://analysis.secfilings.com/articles/85-the-non-invasive-advantage-of-endonovo-therapeutics-endv-electroceuticals
Founded in 2004, SECFilings.com provides free real time filing alerts to over 600,000 registered members and offers services to help public companies grow their audience of interested investors.
Except for the historical information presented herein, matters discussed in this release contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC, which owns SECFilings.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. Emerging Growth LLC may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. For full disclosure please visit: http://secfilings.com/Disclaimer.aspx.